How to Read MOTS-C COA? (Quality Analysis Explained)
How to Read MOTS-C COA? (Quality Analysis Explained) Research conducted at the University of Southern California identified MOTS-C as a mitochondrial-derived peptide in 2015, but the compound's clinical potential depends entirely on purity. And purity depends
How to Read MOTS-C COA? (Quality Analysis Explained)
Research conducted at the University of Southern California identified MOTS-C as a mitochondrial-derived peptide in 2015, but the compound's clinical potential depends entirely on purity. And purity depends on synthesis quality you can't assess by looking at a vial. A 2023 analysis published in the Journal of Pharmaceutical and Biomedical Analysis found that up to 40% of research-grade peptides sold online contained <90% purity when third-party tested, despite vendor claims of >98%. The gap between what you ordered and what arrives isn't visible until you read the Certificate of Analysis.
Our team works exclusively with 503B-registered facilities that conduct full analytical testing on every synthesis batch. The difference between usable research material and expensive saline comes down to three documents most researchers never open.
How do you read a MOTS-C Certificate of Analysis?
A MOTS-C Certificate of Analysis (COA) documents analytical test results verifying peptide purity, sequence accuracy, and contaminant levels through High-Performance Liquid Chromatography (HPLC) and mass spectrometry. The critical data points are purity percentage (target ≥98%), molecular weight confirmation (1599.85 Da for MOTS-C), and endotoxin levels (must be <1.0 EU/mg). Each COA should reference the specific batch number on your vial and include the testing laboratory's name, date, and analytical method used.
Direct Answer: What the COA Actually Tells You
Most researchers assume a COA is a rubber-stamp approval document. It's not. The COA is a detailed report of what was found in the powder during third-party analysis. Not what the manufacturer intended to synthesise. The distinction matters because synthesis byproducts, incomplete sequences, and residual solvents are present in every peptide batch to some degree. The question isn't whether impurities exist. It's whether they fall within acceptable research-grade limits.
This article covers how to read MOTS-C COA data fields, interpret HPLC purity graphs, verify molecular weight accuracy through mass spectrometry, and identify the red flags that indicate compromised product quality before reconstitution.
Step 1: Verify the Batch Number Matches Your Vial Label
The batch number printed on your MOTS-C vial must match the batch number listed on the COA exactly. This is the single most important verification step and the one most commonly skipped. If the batch numbers don't match, you're reading analytical data for a different synthesis run. The purity, molecular weight, and contaminant levels documented in that COA do not apply to the product in your hand.
Legitimate peptide suppliers link each COA to a specific batch through a unique alphanumeric identifier. At Real Peptides, every vial label includes a batch code that corresponds to the exact synthesis date and analytical test results archived in our quality system. Cross-reference this code before evaluating any other COA field. If it doesn't match, contact the supplier immediately.
Batch-to-batch variation in peptide synthesis is normal. Purity can range from 96.8% to 99.2% across different runs using identical protocols, which is why each batch requires independent testing. A COA from a previous synthesis tells you nothing about the current vial's composition. Generic COAs. Documents labelled 'representative' or listing no batch number at all. Are marketing materials, not analytical reports.
Step 2: Interpret HPLC Purity Percentage and Peak Integration
High-Performance Liquid Chromatography (HPLC) separates peptide molecules from synthesis impurities based on retention time as the sample passes through a chromatography column. The output is a chromatogram. A graph showing UV absorbance peaks at different time points. The tallest peak represents the target peptide (MOTS-C in this case), and smaller peaks represent impurities like truncated sequences, deletion peptides, and residual coupling reagents.
Purity percentage is calculated by dividing the area under the main peptide peak by the total area under all peaks, then multiplying by 100. Research-grade MOTS-C should show purity ≥98% by HPLC, meaning impurities account for <2% of the total peptide content. A COA reporting 97.3% purity indicates 2.7% of the material is something other than the intended 16-amino-acid sequence. Acceptable for some research applications, insufficient for others.
The chromatogram itself reveals more than the summary percentage. Look for the retention time of the main peak. For MOTS-C, this is typically between 12–16 minutes depending on the column and mobile phase used. If you're comparing COAs across multiple batches or suppliers, consistent retention time suggests consistent synthesis conditions. Significant variation (>2 minutes) indicates different analytical methods were used, making direct purity comparisons unreliable.
Step 3: Confirm Molecular Weight Through Mass Spectrometry Data
Mass spectrometry (MS) confirms that the peptide in the vial has the correct molecular weight for MOTS-C. The theoretical molecular weight of MOTS-C is 1599.85 Daltons (Da). This is the sum of all 16 amino acids in the sequence MRWQEMGYIFYPRKLR. The MS section of the COA should list an observed molecular weight within ±1.0 Da of this value. If the observed weight is 1598.9 Da or 1600.7 Da, the sequence is correct. If it's 1543 Da or 1672 Da, something went wrong during synthesis.
Electrospray ionisation mass spectrometry (ESI-MS) is the standard technique for peptide molecular weight verification. The peptide is ionised and passed through a mass analyser that separates molecules by their mass-to-charge ratio (m/z). MOTS-C typically produces a doubly charged ion at m/z 800.4 and a triply charged ion at m/z 533.9. Both correspond to the correct molecular weight when the charge state is factored in. The COA should report the deconvoluted mass (the actual molecular weight after removing charge effects), not just the m/z ratios.
Why molecular weight matters: HPLC purity can be misleadingly high if the impurities present have similar UV absorbance and retention times to the target peptide. Mass spectrometry provides independent confirmation that the molecule eluting at the main HPLC peak is actually MOTS-C and not a structurally similar peptide with one or two amino acid substitutions. Without MS confirmation, you're assuming the tall peak on the chromatogram is the compound you ordered.
MOTS-C COA: Quality Metrics Comparison
HPLC Purity
Percentage of target peptide vs total peptide content
≥98.0%
Synthesis byproducts, incomplete sequences, residual coupling agents
Primary indicator of product quality. Purity <97% suggests poor synthesis control or inadequate purification
Mass Spectrometry
Molecular weight confirmation
1599.85 Da ±1.0 Da
Wrong sequence, amino acid substitutions, or degradation
Independent verification that the HPLC main peak is actually MOTS-C. Critical for research reproducibility
Endotoxin Testing (LAL)
Bacterial endotoxin contamination
<1.0 EU/mg
Contamination during synthesis or lyophilisation
Essential for any in vivo application. High endotoxin triggers immune responses that confound experimental results
Peptide Content
Total peptide as percentage of net weight
70–85% (rest is counterions and residual water)
Incorrect fill weight or excessive hygroscopic water absorption
Low peptide content means you're dosing less active compound than calculated. Affects concentration accuracy
Appearance
Visual inspection of lyophilised powder
White to off-white powder, no discoloration
Oxidation, degradation, or thermal damage during lyophilisation
Yellowing or clumping visible before opening suggests storage failure or manufacturing defects
Key Takeaways
The batch number on the COA must match the batch number on your vial label exactly. Mismatched numbers mean the analytical data doesn't apply to your product.
HPLC purity ≥98% is the baseline for research-grade MOTS-C. Purity <97% indicates excessive synthesis byproducts that may interfere with experimental outcomes.
Mass spectrometry confirms the molecular weight is 1599.85 Da ±1.0 Da. This verifies the amino acid sequence is correct and the HPLC peak represents MOTS-C, not a structurally similar impurity.
Endotoxin levels must be <1.0 EU/mg for any in vivo research application. Higher levels trigger immune responses that confound metabolic and mitochondrial function studies.
Peptide content (70–85% of net weight) determines the actual dose delivered after reconstitution. Low peptide content means you're administering less compound than your calculations assume.
A complete COA includes batch-specific HPLC chromatogram, mass spectrum, endotoxin test results, and peptide content analysis. Generic 'representative' COAs are not analytical reports.
What If: MOTS-C COA Scenarios
What If the HPLC Purity Is Listed as 96.4% Instead of ≥98%?
Use the batch for preliminary studies only. Not for final experiments intended for publication. The 3.6% impurity fraction may include deletion sequences (MOTS-C missing one or more amino acids) or acetylated variants that don't activate the same mitochondrial pathways as the native peptide. If you're studying MOTS-C effects on insulin sensitivity or AMPK activation, that 3.6% isn't inert filler. It's potentially bioactive contaminants that skew your dose-response curves. Contact the supplier for batch replacement or request a discount with documentation that purity falls below research-grade standard.
What If the Mass Spectrometry Data Shows 1598.2 Da Instead of 1599.85 Da?
A molecular weight 1.65 Da lower than expected suggests one amino acid substitution or deletion occurred during synthesis. The most common error is loss of a single arginine (R) or lysine (K) residue. Both have molecular weights close to the observed discrepancy. This is not MOTS-C. The biological activity will differ meaningfully from published literature, making your experimental results non-comparable. Reject the batch immediately. Do not attempt to 'correct' the dose or use it for any purpose.
What If No Endotoxin Data Is Listed on the COA?
Assume endotoxin testing was not performed. Which means the peptide is unsuitable for any in vivo application. Bacterial endotoxins (lipopolysaccharides) are potent immune activators that remain stable through lyophilisation and reconstitution. Even trace amounts (<0.5 EU/mg) can induce fever, inflammatory cytokine release, and altered metabolic signalling in rodent models. If your research involves cell culture only, endotoxin absence is less critical but still relevant. Contaminated peptides can activate TLR4 receptors in macrophages and confound inflammation studies.
The Unfiltered Truth About Peptide COAs
Here's the honest answer: most peptide suppliers know researchers won't read the COA in detail. So they optimise the document for credibility theatre, not analytical transparency. A COA with a university letterhead, professional formatting, and impressive-looking graphs creates the appearance of rigorous testing without necessarily providing the data needed to verify product quality. The dead giveaway is a COA that lists HPLC purity but includes no chromatogram, or reports molecular weight with no mass spectrum attached.
The second giveaway is batch number ambiguity. If the COA is labelled 'representative analysis' or 'typical results', it's not tied to the specific synthesis run that produced your vial. That document tells you what the supplier is capable of producing under ideal conditions. Not what's actually inside the bottle you're holding. Every legitimate analytical report includes the synthesis date, testing date, and batch identifier. If those fields are blank or generic, you're looking at marketing material formatted to resemble analytical data.
We've reviewed hundreds of peptide COAs across the research supply market. The pattern is consistent: suppliers targeting the research-grade segment provide complete analytical packages with chromatograms, spectra, and endotoxin results. Suppliers targeting price-sensitive buyers provide summary documents with purity percentages and no supporting data. You can tell which customer segment you're in by what's included. Or more often, what's missing. From the COA.
Understanding Peptide Content vs Net Weight
Peptide content is reported as a percentage of the net weight in the vial. A 5mg vial of MOTS-C with 78% peptide content contains 3.9mg of actual peptide and 1.1mg of counterions (typically acetate or trifluoroacetate from the purification process) plus residual moisture. This distinction affects reconstitution calculations. If you assume 5mg peptide and dissolve it in 5mL bacteriostatic water, your final concentration is 0.78mg/mL, not 1mg/mL.
The counterion fraction is unavoidable. Peptides are purified through reversed-phase HPLC using acidic mobile phases, which leaves trifluoroacetic acid (TFA) or acetic acid bound to basic amino acid residues like arginine and lysine. During lyophilisation, these counterions remain associated with the peptide structure. Peptide content between 70–85% is normal and expected. Values below 70% suggest either excessive moisture absorption (storage failure) or incomplete lyophilisation (manufacturing defect).
When calculating reconstitution volumes, always use the peptide content value from the COA, not the nominal fill weight on the vial label. If your experimental protocol requires 10mg MOTS-C total and the vial contains 78% peptide content, you need 12.8mg net weight to deliver 10mg active peptide. Ignoring this adjustment systematically underdoses every study by 22%. Enough to shift dose-response curves and compromise reproducibility.
Without a COA tied to your specific vial's batch number, there's no way to verify what arrived. The label might say '10mg MOTS-C >98% purity'. But those numbers mean nothing without independent third-party analysis documented in a batch-specific report. At Real Peptides, every synthesis batch undergoes HPLC, mass spectrometry, and endotoxin testing before release, and the full analytical package is available with every order. That's not a differentiator. It's the baseline standard for research-grade material.
If the batch numbers don't match, if the molecular weight is wrong, or if no chromatogram is attached. The peptide in your hand is not verified. Use it anyway and you're running experiments on an undefined compound. That's the reality most suppliers won't state plainly, because acknowledging it would require actually providing complete analytical documentation for every batch shipped.
Frequently Asked Questions
Cross-reference the batch number or lot number printed on your vial label with the batch identifier listed at the top of the Certificate of Analysis. If these numbers don’t match exactly, the COA documents a different synthesis run and the purity, molecular weight, and contaminant data do not apply to your product. Legitimate suppliers provide batch-specific COAs — never generic ‘representative’ documents.
Research-grade MOTS-C should demonstrate purity ≥98% by High-Performance Liquid Chromatography. Purity between 97–98% is marginally acceptable for preliminary studies, but below 97% indicates excessive synthesis byproducts that may interfere with experimental reproducibility. For publication-grade research, particularly metabolic or mitochondrial function studies, 98% or higher is the standard.
No. The observed molecular weight must be within ±1.0 Daltons of the theoretical value (1599.85 Da for MOTS-C). A variance beyond this range indicates amino acid substitution, sequence deletion, or synthesis error — meaning the compound is not MOTS-C and will not produce the biological activity documented in published literature. Reject any batch with molecular weight discrepancies exceeding ±1.0 Da.
Purity and peptide content measure different things. HPLC purity (98%) refers to the percentage of target peptide versus other peptides or synthesis impurities. Peptide content (78%) refers to the percentage of the total vial weight that is peptide versus counterions (acetate, trifluoroacetate) and residual moisture. Both values are necessary — purity confirms synthesis quality, while peptide content determines actual dosing calculations.
Endotoxin levels should be <1.0 EU/mg for any research application, and ideally <0.5 EU/mg for cell culture work involving immune cells or inflammatory pathway studies. Bacterial endotoxins activate TLR4 receptors and can confound results even in in vitro systems. If the COA does not include endotoxin data (typically measured via Limulus Amebocyte Lysate assay), the peptide was not tested and should be considered unsuitable for biological applications.
MOTS-C has a molecular weight of 1599.85 Da and 16 amino acids, making it smaller than humanin (2673 Da, 24 amino acids) but similar in synthesis complexity. All mitochondrial-derived peptides require identical analytical standards — HPLC purity ≥98%, mass spectrometry confirmation, and endotoxin testing <1.0 EU/mg. The critical difference is sequence verification: MOTS-C contains arginine and lysine residues that bind counterions more readily than humanin, often resulting in slightly lower peptide content percentages (75–80% vs 80–85%).
Request the full analytical report including the HPLC chromatogram and mass spectrum. A complete COA includes visual data — the chromatogram shows the separation of MOTS-C from impurities over time, and the mass spectrum confirms molecular weight. Summary documents listing only a purity percentage without supporting graphs are insufficient for research-grade verification. If the supplier cannot or will not provide complete analytical documentation, find a different supplier.
COA trustworthiness depends on the testing laboratory, not the synthesis location. The COA should list the name of the independent third-party lab that performed HPLC and mass spectrometry analysis — not just ‘in-house testing’ or ‘manufacturer analysis’. Reputable overseas facilities use accredited analytical labs (often in the same countries as the synthesis facility) and provide full test reports with instrument parameters, analyst signatures, and ISO/GMP certifications. The red flag is vague language about ‘quality assurance’ with no named testing institution.
Once per batch only. A COA documents the analytical results at the time of synthesis and initial testing — it does not change unless the peptide is retested after extended storage or if degradation is suspected. If you’re storing lyophilised MOTS-C long-term (>12 months at −20°C), consider requesting stability testing or re-analysis to confirm the peptide has not degraded, but this is separate from the original batch COA.
A ‘representative COA’ or ‘typical analysis’ is a generic document showing what the supplier is capable of producing under ideal conditions — it is not tied to the specific batch in your vial. This means the purity, molecular weight, and contaminant data listed may not reflect your actual product. Batch-to-batch variation is normal in peptide synthesis, which is why every batch requires independent testing. Representative COAs are marketing documents, not analytical verification, and should not be accepted for research-grade material.